Navigation Links
MDS Reports Third Quarter 2007 Results
Date:9/6/2007

ities in both the current and prior periods and recalculate the figures for the prior period using the exchange rates that were in effect for the current period. We provide a reconciliation that shows the differences between reported and organic growth figures highlighting the variances caused by currency fluctuations and those caused by business acquisitions or divestitures.

Substantially all of the business of the Sciex division of MDS Analytical Technologies is conducted through joint ventures. Under the terms of these joint ventures, we are entitled to a 50% share of the net earnings of the worldwide business that we conduct with our partners in these joint ventures. These earnings include a share of the profits generated by our partners that are paid to the joint ventures as profit sharing and which do not qualify as revenues for the joint ventures.

Under Canadian GAAP, we report only our direct revenues and our share of revenues from the joint ventures including appropriate intercompany eliminations, and, consequently, we do not report our share of all end-user revenues, despite the fact that these other businesses contribute to our profitability. In order to provide readers with a better understanding of the drivers of profitability for the Sciex division of MDS Analytical Technologies, in addition to the organic growth of our reported revenues, we also report growth in end-user revenues as reported by our joint venture partners. This figure provides management and readers with additional information on the performance of our global business, including trends in end customer demand and our performance relative to the overall market.

We are unable to provide the organic growth in this measure because we do not have access to the underlying currency data.

MDS Pharma Services measures and tracks contract backlog. Contract backlog is a non-GAAP measure that we define to include the amount of contract value (excluding amounts associated wit
'/>"/>

SOURCE MDS Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine news :

1. Autopsy reports could be valuable and informative
2. China reports declining number of SARS Cases
3. Russia Reports First SARS Case
4. Research reports that c-section deliveries are rising
5. Jharkhand reports 13,000 Malaria cases
6. Uganda Reports Failure To Contain Sleeping Sickness
7. WHO reports 36 million deaths world wide due to chronic diseases
8. Reports of Hantavirus infection in India raise concerns
9. Controversy Surrounding The HIV Positive Reports Of One-Year Girl In Kerala
10. China Reports Yet Another Bird Flu Case
11. China reports seventh bird flu victim

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)...rsity researchers, from the School of Medicine,s D...ic pathways by which products of lipid peroxidatio..., are metabolized. The pathways were identified by... analysis. The findings shed new light on the mech...butyrate, also known as "the date rape drug." The ...
(Date:12/4/2009)...ure done immediately or 3 weeks later, study shows...Timing of surgical repair or reconstruction of mul...t outcome, a new study has found. , Multiple-li...slocations that can occur in high-impact car crash...rm surgery to repair these injuries hasn,t been de...
(Date:12/4/2009)...r Applauds Historic Effort but Points out Potentia...n Final Health Care Reform ,, NEW YORK, Dec. ...rnal of Medicine today published a Perspective o...hored by Irwin Redlener, M.D., president, Children...isaster Preparedness and Professor of Clinical Pop...
(Date:12/4/2009)...through hookah, research shows , , FRIDA...afer than cigarettes for smoking tobacco, research...oke tobacco with a water pipe inhale carbon monoxi... disease and nicotine addiction. , The study in...bacco using a water pipe and a single cigarette. A...
(Date:12/4/2009)... Dec. 4 When the spread ...epartment of Health Services needed to get more in...fore. Join Sonic Foundry, Inc. (Nasdaq: SOFO ),...sting and knowledge management, for a live webinar... of Health Services, will share how in-house webca...
Breaking Medicine News(10 mins):Health News:Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week' 2Health News:Timing of Multiple-Ligament Knee Surgery May Not Matter 2Health News:New England Journal of Medicine Perspective by Irwin Redlener, MD, Addresses Health Care Reform 2Health News:Water Pipes No Safer Than Cigarettes 2Health News:Live Webinar: Pandemic + Recession = Webcasting: Cost-Effective Streaming for Public Health Communications 2Health News:Live Webinar: Pandemic + Recession = Webcasting: Cost-Effective Streaming for Public Health Communications 3
...s Corp. (Nasdaq:,HMSY) today announced that it wil...onference, which will be held January 7-10, 2008 a...: http://www.newscom.com/cgi-bin/prnh/20030304/NY...ast of the Company,s presentation can be accessed ...
...nix,Pharmaceuticals, Inc. (Nasdaq: IDIX ) announc...porate overview, including an update of the compan..., at the upcoming JP Morgan 26th,Annual Healthcare...entation can be accessed,under "Calendar of Events...
...am for Lead Product, MENLO PARK, Calif., Dec. 20 ...t it has completed a private placement financing,r...opment of the company,s,novel antiplatelet therapy...on,from Prospect Venture Partners, Ridgeback Capit...
...-Opportunities program of Agriculture and ..., ON, Dec. 20 /PRNewswire-FirstCall/ - Bioniche Li...hnology-driven Canadian,biopharmaceutical company,... Ontario. The $5 million repayable,contribution ha...
..., 2007 Wiley-Blackwell, the scientific, technical...n Wiley & Sons, Inc (NYSE: JWa), (NYSE: JWb), and ...anisation dedicated to improving healthcare decisi...World Banks list of low-income economies (countrie...
...dds, study found , THURSDAY, Dec. 20 (HealthDay Ne...cy can boost a child,s risk of developing allergie...nska Institute, Stockholm, analyzed questionnaires...s, 2 years and 4 years. In addition, the researche...
Other Medicine News:Health News:Cogentus Pharmaceuticals Completes $62.5 Million Private Financing 2Health News:Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario 2Health News:Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario 3Health News:Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario 4Health News:Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario 5Health News:Low-income countries now have free, one-click access to Cochrane Library 2Health News:Parents' Smoking Boosts Child's Allergy Risk 2
(Date:12/4/2009)..., ANNAPOLIS, Md., Dec. 4 /PRNewswire-FirstCall/ -...se company developing medical countermeasures agai...ay the presentation of new data from the Company,s...zed recombinant Protective Antigen (rPA) based ant...er 16 months at various temperatures up to and inc...
(Date:12/4/2009)..., SAN DIEGO, Calif., Dec. 4 Sunev...ce company, today announced the appointment of Phi...fficer. In this role, Mr. Ranker will lead all Su...s including finance, accounting, IT, IR, administr...the Company,s senior management team. ,, "One ...
(Date:12/4/2009)..., BETHESDA, Md., Dec. 4 Drs. Neal ...prostate-specific antigen (PSA) recurrence from th...iochemical recurrence rate in a Phase III pivotal ...ection) or monthly leuprolide in prostate cancer p...ate cancer patients who received FIRMAGON 240/80 m...
Breaking Medicine Technology:PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 3PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 4PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 5Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 2Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 3Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 4Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4Middle Age Heart Risk Factors Shorten Mens Lives 57598 1Middle Age Heart Risk Factors Shorten Mens Lives 57598 2Middle Age Heart Risk Factors Shorten Mens Lives 57598 3Northwest Hospital 26 Medical Center to Join UW Medicine 57596 1Northwest Hospital 26 Medical Center to Join UW Medicine 57596 2Northwest Hospital 26 Medical Center to Join UW Medicine 57596 3U S Chamber 3A Medical Liability Reform Must Have Teeth to be Effective 57594 1
...r and Imaging Study) Results Demonstrate ...SAN DIEGO, Calif., Sept. 2 Volcano,Corporation (N...nufacturer of,intravascular ultrasound (IVUS) and ...oday the use of its VH(R) IVUS (Virtual Histology ...d Biomarker and Imaging Study). In,the study, Volc...
...sty and Stenting Safe and Effective in Patients ...t Surgery, WASHINGTON, Sept. 1 Data announced to...atients with very complex coronary,artery disease ...nd,drug-eluting stents rather than open-heart surg...hy and Interventions (SCAI). The one-year results,...
Other Medicine Technology:Volcano's VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKline's Novel Investigational Compound, Darapladib 2Volcano's VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKline's Novel Investigational Compound, Darapladib 3Volcano's VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKline's Novel Investigational Compound, Darapladib 4SCAI: SYNTAX Data Show PCI Is a Good Option for Patients With Complex Coronary Artery Disease 2SCAI: SYNTAX Data Show PCI Is a Good Option for Patients With Complex Coronary Artery Disease 3
Endoscope
Neuroview 1.2 mm Neuroendoscopes
...atch is a synthetic absorbable implant for the bri...s. Ethisorb Dura Patch is pliable, regardless of b...e, care must be taken, while implanting, to ensure...de is oriented towards the cortex or the spinal co...
IDS-300 Electrosurgical Generator
Medicine Products: